Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Bristol Myers Squibb is ready for a data showdown with Merck as they move their respective PD-1 inhibitors into earlier lines of melanoma treatment.

Taking the stage at the annual meeting of the Society for Melanoma Research, Bristol Myers reported that in the Phase III CheckMate-76K trial, Opdivo reduced the risk of recurrence or death by 58% — translating to a hazard ratio of 0.42 on the primary endpoint of recurrence-free survival (p < 0.0001).